Oncolytics Biotech (ONCY) Cash from Discontinued Operations (2009 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Cash from Discontinued Operations of 4832849.4 for Q3 2025, down 36.44% year-over-year from 7603564.66 in Q3 2024, and down 22.4% quarter-over-quarter from 3948489.08 in Q2 2025.
Oncolytics Biotech (ONCY) Cash from Discontinued Operations (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Cash from Discontinued Operations for 17 consecutive years, with 4832849.4 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Discontinued Operations fell 36.44% year-over-year to 4832849.4; the TTM figure through Sep 2025 stood at 18926454.11 (down 1.93% YoY), while the FY2024 annual figure was 19695950.47, up 6.59% from the prior year.
- Cash from Discontinued Operations fell to 4832849.4 in Q3 2025 per ONCY's latest filing, from 3948489.08 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 2965526.77 in Q3 2021 and bottomed at 6301790.12 in Q2 2023.
- Historically, Cash from Discontinued Operations has averaged 4736800.69 across 5 years, with a median of 4832849.4 in 2025.
- On a YoY basis, Cash from Discontinued Operations climbed as much as 35.46% in 2021 and fell as far as 49.13% in 2021.
- Oncolytics Biotech's Cash from Discontinued Operations stood at 5025518.31 in 2021, then increased by 12.94% to 4375278.76 in 2022, then retreated by 2.81% to 4498295.57 in 2023, then declined by 24.86% to 5616552.36 in 2024, then grew by 13.95% to 4832849.4 in 2025.
- Business Quant data shows ONCY's Cash from Discontinued Operations at 4832849.4 in Q3 2025, 3948489.08 in Q2 2025, and 4528563.26 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -4.83 Mn |
| Sep 30, 2025 | -4.83 Mn |
| Jun 30, 2025 | -3.95 Mn |
| Jun 30, 2025 | -3.95 Mn |
| Mar 31, 2025 | -4.53 Mn |
| Mar 31, 2025 | -4.53 Mn |
| Dec 31, 2024 | -5.62 Mn |
| Dec 31, 2024 | -5.62 Mn |
| Sep 30, 2024 | -3.54 Mn |
| Sep 30, 2024 | -3.54 Mn |
| Jun 30, 2024 | -4.99 Mn |
| Jun 30, 2024 | -4.99 Mn |
| Mar 31, 2024 | -5.54 Mn |
| Mar 31, 2024 | -5.54 Mn |
| Dec 31, 2023 | -4.50 Mn |
| Dec 31, 2023 | -4.50 Mn |
| Sep 30, 2023 | -4.50 Mn |
| Sep 30, 2023 | -4.50 Mn |
| Jun 30, 2023 | -6.30 Mn |
| Jun 30, 2023 | -6.30 Mn |